Sonidegib diphosphate

SKU: orb1308134

Description

Sonidegib diphosphate is a potent and selective Smoothened (Smo) antagonist, with IC50 values of 1.3 nM and 2.5 nM for murine and human targets, respectively. This tool compound is widely used in vitro and in vivo for researching Hedgehog pathway-driven cancers, such as basal cell carcinoma and medulloblastoma.

Research Area

Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1218778-77-8
• MW: 681.49
• Purity: 99.86%
• Formula: C₂₆H₃₂F₃N₃O₁₁P₂
• SMILES: OP(O)(O)=O.OP(O)(O)=O.C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1
• Target: Smo
• Solubility: DMSO:99 mg/mL (145.27 mM);H2O:Insoluble;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (4.84 mM)

Bioactivity

• Target IC50:
  Smo:2.5 nM (IC50)|Smo (mouse):1.3 nM (IC50)
• In Vivo:
  METHODS: A transgenic EGFP/SCLtTA/TRE-BCR-ABL mouse model was used, and mice were treated with nilotinib (50 mg/kg, gavage, daily, 3 weeks), Sonidegib diphosphate (LDE225 diphosphate) (80 mg / kg, gavage, daily, 3 weeks), Sonidegib diphosphate (LDE225 diphosphate) + nilotinib, or carrier alone (control) treatment, to study the effects of Sonidegib diphosphate (LDE225 diphosphate) treatment on CML LSC in vivo. RESULTS The cohort treated with Sonidegib diphosphate (LDE225 diphosphate) had a small, non-significant incremental reduction in mean body weight; Sonidegib diphosphate (LDE225 diphosphate) alone reduced splenic LTHSC but did not significantly reduce GMP and CMP ; Sonidegib diphosphate (LDE225 diphosphate) + nilotinib significantly reduced GMP, CMP, and LTHSC in the spleen. in contrast, in the BM of mice treated with Sonidegib diphosphate (LDE225 diphosphate), nilotinib, or the combination there were no significant changes in the amounts of GMP, CMP and LTHSC.
• In Vitro:
  METHODS: Sonidegib diphosphate (LDE225 diphosphate) (10, 100nM, 72 hours) was treated in CD34 CP-CML cells and its effect on GLI1 expression in CD34 CP-CML cells was assessed. RESULTS No changes in GLI1 were observed in CD34 CP-CML cells at 6 and 24 h; at 72 h, GLI1 was significantly downregulated (10 nM; 0.78-fold and 100 nM; 0.73-fold).

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LDE 225, LDE 225 Diphosphate, LDE225, LDE-225, LDE225 diphosphate, LDE-225 Diphosphate, Erismodegib, Erismodegib diphosphate, hSmo, NVP-LDE 225, NVP-LDE 225 diphosphate, NVP-LDE225, NVP-LDE-225, NVP-LDE-225 Diphosphate, mSmo, Smo, Sonidegib

Compound Identifiers

PubChem CID

45138699